**Supplementary Table 1. Baseline characteristics of study participants**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sl No | **Total patients (*n*=439)** | **No ACLF (*n*=326)** | **ACLF (*n*=113)** | ***p*** |
| 1 | Age | 50.81±13.20 | 45.63±9.95 | <0.001 |
| 2 | Gender (Male) | 80.1% (261/326) | 92.0% (104/113) | 0.003 |
| 3 | BMI (kg/mt2) | 21.27±3.90 | 22.16±3.78 | 0.036 |
| 4 | MAP (mmHg) | 85.46±9.86 | 83.32±11.35 | 0.056 |
| 5 | Total leucocyte count (103cells/dL) | 7800 (6200-10050) | 9800 (7700-12900) | <0.001 |
| 6 | Serum bilirubin (total) (mg/dL) | 1.90 (0.90-3.33) | 9.20 (6.10-14.60) | <0.001 |
| 7 | Serum creatinine (mg/dL) | 1.10 (0.90-1.70) | 1.50 (1.00-2.50) | 0.004 |
| 8 | Urea (mg/dL) | 32.00 (22-51) | 37 (23-68) | 0.043 |
| 9 | Serum protein (g/dL) | 6.37±0.91 | 6.53±0.93 | 0.123 |
| 10 | Serum albumin (g/dL) | 2.75±0.50 | 2.49±0.39 | <0.001 |
| 11 | Serum sodium (mEq/L) | 133.55±14.10 | 130.42±8.27 | 0.026 |
| 12 | Serum potassium(mEq/L) | 4.19±1.31 | 4.22±0.98 | 0.830 |
| 13 | SAAG | 2.25±0.53 | 2.09±0.43 | <0.001 |
| 14 | INR | 1.60±0.46 | 2.61±1.22 | <0.001 |
| 15 | MELD (UNOS) | 16.99±6.29 | 29.85±8.40 | <0.001 |
| 16 | MELD (Na+) | 19.92±6.76 | 31.74±6.93 | <0.001 |
| 17 | CTP score | 10.12±2.26 | 12.89±1.67 | <0.001 |
| 18 | Duration of hospital stay (days) | 4 (3-6) | 5 (4-8) | 0.031 |
| 19 | 28 days survival | 82.2% (268/326) | 53.9% (61/113) | <0.001 |
| 20 | 90 days survival | 62.6% (204/326) | 33.6% (38/113) | <0.001 |

Data are presented as mean (standard deviation), median (interquartile range), or frequency (%).

Abbreviations: ACLF, acute-on-chronic liver failure; AKI, acute kidney injury; BMI, body mass index; CTP, Child-Turcotte-Pugh classification score; INR, international normalized ratio; MAP, mean arterial pressure; MELD, model for end-stage liver disease); SAAG, serum ascites albumin gradient.